Breaking News Instant updates and real-time market news.

ALDR

Alder Biopharmaceuticals

$19.00

-0.2 (-1.04%)

05:03
08/06/18
08/06
05:03
08/06/18
05:03

Alder Biopharmaceuticals initiated with an Overweight at Piper Jaffray

Piper Jaffray analyst Danielle Brill started Alder Biopharmaceuticals with an Overweight rating and $28 price target. Alder is undervalued despite having a "late-stage, de-risked, and differentiated" asset that addresses the large, under-served migraine population, Brill tells investors in a research note. The analyst finds the stock "very attractive at current levels."

  • 07

    Aug

ALDR Alder Biopharmaceuticals
$19.00

-0.2 (-1.04%)

05/31/18
RBCM
05/31/18
NO CHANGE
Target $24
RBCM
Outperform
Developments at Allergan, Biogen indirectly positive for Alder, says RBC Capital
RBC Capital analyst Brian Abrahams noted that both Allergan (AGN) and Biogen (BIIB) have been viewed as companies that could potentially be interested in acquiring or partnering with Alder Biopharmaceuticals (ALDR) and he makes the case that developments in the past day or so for both of those large-cap drugmakers are indirectly positive for Alder. In terms of Allergan, Abrahams thinks the company stating that it plans to keep a primary care infrastructure to sell CGRPs and other CNS products maintains the likelihood they might have interest in Alder's eptinezumab either as an acquisition or in a partnership. In terms of Biogen, Abrahams thinks the company's hiring of a leader for a newly-created corporate development function who has extensive experience in business development potentially lays the groundwork for them to explore assets such as eptinezumab. The analyst maintains an Outperform rating and $24 price target on Alder shares.
06/11/18
WELS
06/11/18
NO CHANGE
Target $240
WELS
Outperform
Allergan migraine data on lower end of relative efficiency, says Wells Fargo
Wells Fargo analyst David Maris says his initial review suggests Allergan's (AGN) atogepant's Phase IIb data are "relatively in-line but on the lower end of the efficacy" demonstrated by the calcitonin gene-related peptide migraine treatments in Phase III trials. Atogepant is expected to face competition from Amgen (AMGN)/Novartis (NVS), Eli Lilly (LLY) and Teva (TEVA), which are all developing injectable anti-CGRP treatments, as well as Alder Biopharmaceuticals (ALDR), which has an infusion-administered anti-CGRP in development, Maris tells investors in a research note. He notes that while Allergan will be following these competitors to the market, atogepant will be differentiated in that it is the only oral prophylactic anti-CGRP therapy. The analyst forecasts $75M in sales for atogepant in 2022. He does not believe many investors are giving Allergan credit for atogepant, meaning the "risk to the downside looks limited." Maris keeps an Outperform rating on Allergan shares.
06/12/18
LEER
06/12/18
NO CHANGE
LEER
Too early to see Allergan's atogepant threatening injectables, says Leerink
Leerink analyst Geoffrey Porges notes that Allergan (AGN) announced positive topline data from a phase IIb/III trial of oral CGRP receptor antagonist atogepant in episodic migraine prevention. The analyst believes this data is certainly positive for Allergan and suggests they may eventually have an oral CGRP medicine approval for both acute and preventative treatment of migraines, However, Porges awaits further data disclosure and larger patient numbers to be convinced about comparing the efficacy of atogepant to the more advanced injectable CGRP medicines in development. With regard to Amgen (AMGN) and Alder (ALDR), who both have injectable CGRP antibodies for migraine prevention, potential competitive erosion from orals is still several years away and he continues to see the more severe chronic migraine population as being a more meaningful commercial opportunity for this class.
06/27/18
NEED
06/27/18
INITIATION
Target $28
NEED
Buy
Alder Biopharmaceuticals assumed with a Buy at Needham
Needham analyst Serge Belanger assumed Alder Biopharmaceuticals with a Buy rating and a price target of $28, saying the company is positioned as a "rare pure-play migraine story". Belanger cites the positive pivotal phase 3 trial data for its Eptinezumab drug where it met all the endpoints and demonstrated an efficacy profile relative to competitive treatments. The analyst believes that Eptinezumab will appeal to "most severe of migraine patients where it will generate blockbuster-level sales" of over $1B.

TODAY'S FREE FLY STORIES

NVDA

Nvidia

$168.91

-0.99 (-0.58%)

, MSFT

Microsoft

$117.60

1.7 (1.47%)

17:58
03/18/19
03/18
17:58
03/18/19
17:58
Hot Stocks
Nvidia says real-time ray tracing integrated into Unreal, Unity engines »

Nvidia (NVDA) announced…

NVDA

Nvidia

$168.91

-0.99 (-0.58%)

MSFT

Microsoft

$117.60

1.7 (1.47%)

TCEHY

Tencent

$0.00

(0.00%)

KKR

KKR

$24.51

0.35 (1.45%)

DIS

Disney

$113.07

-1.89 (-1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 19

    Mar

  • 21

    Mar

  • 04

    Apr

  • 11

    Apr

GOOG

Alphabet

$1,183.66

-1.6 (-0.13%)

, GOOGL

Alphabet Class A

$1,188.09

-3.69 (-0.31%)

17:53
03/18/19
03/18
17:53
03/18/19
17:53
Periodicals
Google expected to announce new cloud-based gaming console at GDC, CBS News says »

According to CBS…

GOOG

Alphabet

$1,183.66

-1.6 (-0.13%)

GOOGL

Alphabet Class A

$1,188.09

-3.69 (-0.31%)

MSFT

Microsoft

$117.60

1.7 (1.47%)

NTDOY

Nintendo

$0.00

(0.00%)

SNE

Sony

$46.10

-0.16 (-0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 27

    Mar

  • 04

    Apr

  • 29

    Apr

  • 29

    Apr

  • 27

    Oct

GLD

SPDR Gold Shares

$123.04

0.07 (0.06%)

17:50
03/18/19
03/18
17:50
03/18/19
17:50
Hot Stocks
SPDR Gold Shares holdings rise to 779.27MT from 771.04MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FDC

First Data

$25.36

-0.285 (-1.11%)

17:40
03/18/19
03/18
17:40
03/18/19
17:40
Hot Stocks
First Data VP Bala Janakiraman sells over 25K shares of company stock »

First Data VP Bala…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Apr

VLKAY

Volkswagen

$0.00

(0.00%)

17:37
03/18/19
03/18
17:37
03/18/19
17:37
Periodicals
Ex-UAW official charged in corruption investigation at Fiat Chrysler, WSJ says »

Norwood Jewell, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$136.23

2.79 (2.09%)

17:33
03/18/19
03/18
17:33
03/18/19
17:33
Hot Stocks
Valmont announces Nebraska site closure »

This past week, many…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

FLDM

Fluidigm

$13.78

0.12 (0.88%)

17:32
03/18/19
03/18
17:32
03/18/19
17:32
Syndicate
Breaking Syndicate news story on Fluidigm »

Fluidigm files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FOX

21st Century Fox

$51.06

-0.64 (-1.24%)

, FOXA

21st Century Fox

$51.38

-0.57 (-1.10%)

17:26
03/18/19
03/18
17:26
03/18/19
17:26
Hot Stocks
Fox, Disney announces distribution adjustment multiple for acquisition »

Twenty-First Century Fox…

FOX

21st Century Fox

$51.06

-0.64 (-1.24%)

FOXA

21st Century Fox

$51.38

-0.57 (-1.10%)

DIS

Disney

$113.07

-1.89 (-1.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Apr

XYF

X Financial

$6.23

0.715 (12.98%)

17:23
03/18/19
03/18
17:23
03/18/19
17:23
Earnings
X Financial reports Q4 EPS 24c, two estimates 24c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

  • 20

    Mar

CADE

Cadence Bancorp

$20.24

0.51 (2.58%)

17:22
03/18/19
03/18
17:22
03/18/19
17:22
Hot Stocks
Cadence Bancorp President Samuel Tortorici buys almost $1M in company shares »

Cadence Bancorp President…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

CELP

Cypress Energy

$7.41

0.06 (0.82%)

17:22
03/18/19
03/18
17:22
03/18/19
17:22
Syndicate
Breaking Syndicate news story on Cypress Energy »

Cypress Energy files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

JWN

Nordstrom

$44.21

0.465 (1.06%)

17:21
03/18/19
03/18
17:21
03/18/19
17:21
Syndicate
Breaking Syndicate news story on Nordstrom »

Nordstrom files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$171.73

2.13 (1.26%)

17:20
03/18/19
03/18
17:20
03/18/19
17:20
Hot Stocks
General Dynamics awarded $2.04B Navy submarine material contract modification »

General Dynamics has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

FFIN

First Financial

$61.60

0.44 (0.72%)

, MBFI

MB Financial

$47.20

0.63 (1.35%)

17:19
03/18/19
03/18
17:19
03/18/19
17:19
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

First Financial…

FFIN

First Financial

$61.60

0.44 (0.72%)

MBFI

MB Financial

$47.20

0.63 (1.35%)

FOE

Ferro

$18.88

0.125 (0.67%)

FITB

Fifth Third

$28.74

0.42 (1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 16

    Apr

  • 23

    Apr

  • 23

    Apr

FOE

Ferro

$18.88

0.125 (0.67%)

, FFIN

First Financial

$61.60

0.44 (0.72%)

17:17
03/18/19
03/18
17:17
03/18/19
17:17
Hot Stocks
Breaking Hot Stocks news story on Ferro, First Financial »

Ferro to replace First…

FOE

Ferro

$18.88

0.125 (0.67%)

FFIN

First Financial

$61.60

0.44 (0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

FFIN

First Financial

$61.60

0.44 (0.72%)

, MBFI

MB Financial

$47.20

0.63 (1.35%)

17:17
03/18/19
03/18
17:17
03/18/19
17:17
Hot Stocks
First Financial to replace MB Financial in S&P 400 at open on 3/22 »

Fifth Third Bancorp…

FFIN

First Financial

$61.60

0.44 (0.72%)

MBFI

MB Financial

$47.20

0.63 (1.35%)

FITB

Fifth Third

$28.74

0.42 (1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 16

    Apr

  • 23

    Apr

  • 23

    Apr

CUTR

Cutera

$18.00

-0.29 (-1.59%)

17:13
03/18/19
03/18
17:13
03/18/19
17:13
Hot Stocks
Cutera director Daniel Plants buys almost $1.5M in company shares »

Cutera director Daniel…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

SMTX

SMTC Corp.

$4.41

-0.1 (-2.22%)

17:13
03/18/19
03/18
17:13
03/18/19
17:13
Syndicate
Breaking Syndicate news story on SMTC Corp. »

SMTC Corp. files $50M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

  • 28

    May

SNE

Sony

$46.10

-0.16 (-0.35%)

, AAPL

Apple

$188.03

1.83 (0.98%)

17:09
03/18/19
03/18
17:09
03/18/19
17:09
Periodicals
PlayStation Vue now lets Apple TV users watch four channels at once, Verge says »

According to the…

SNE

Sony

$46.10

-0.16 (-0.35%)

AAPL

Apple

$188.03

1.83 (0.98%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRRM

Verra Mobility

$10.89

0.15 (1.40%)

17:08
03/18/19
03/18
17:08
03/18/19
17:08
Earnings
Verra Mobility reports Q4 net ($38.0M) vs. ($29.2M) last year »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

EQH

AXA Equitable

$20.86

0.09 (0.43%)

17:06
03/18/19
03/18
17:06
03/18/19
17:06
Syndicate
AXA Equitable files to sell 40M shares of common stock for holders »

In connection with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$113.07

-1.89 (-1.64%)

17:04
03/18/19
03/18
17:04
03/18/19
17:04
Hot Stocks
ESPN+ to become exclusive distributor of UFC Pay-Per-View events »

UFC and ESPN+ announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Apr

STML

Stemline

$12.92

-0.71 (-5.21%)

17:02
03/18/19
03/18
17:02
03/18/19
17:02
Recommendations
Stemline analyst commentary at Piper Jaffray »

Stemline sees positive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REV

Revlon

$19.39

0.42 (2.21%)

17:02
03/18/19
03/18
17:02
03/18/19
17:02
Hot Stocks
Revlon down 15% after Q4 results miss estimates »

The company also…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Mar

ATR

AptarGroup

$103.69

0.75 (0.73%)

17:01
03/18/19
03/18
17:01
03/18/19
17:01
Hot Stocks
AptarGroup's Bidose approved by FDA for breakthrough treatment of depression »

Aptar Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 01

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.